5-Amino-1MQ
Also called 5-amino-1-methylquinolinium; NNMT inhibitor
An experimental small molecule, not a peptide, that blocks the enzyme NNMT. Mouse studies explored fat tissue, metabolism and aging muscle; there are no human trials.
Overview
What it is
A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that processes a form of vitamin B3.
How it works
NNMT connects to NAD and SAM (a methyl donor) pathways. Blocking it reduced fat production in lab fat cells and changed NAD and SAM levels inside those cells. That does not show it raises NAD throughout the body or boosts energy.
What the research shows
In diet-induced obese mice (nine per group), it reduced weight and fat. A 2021 study combined it with a reduced-calorie diet in mice; authors disclosed ties to a company developing NNMT drugs. In aged mice, grip strength improved but another muscle-performance measure did not. A rat study estimated 38% oral absorption.
Studied for
- Diet-induced obesitymice
- Muscle function in aged micemixed
- Oral absorptionrats
Safety and regulatory status
Safety and side effects
No human side-effect profile, interaction data or long-term safety information exists. A small mouse study with no obvious problems is not a human safety assessment.
Regulatory status
Not approved by the FDA for any use.
Mixing and dosing reference
Reference information only. Read before using this section.
5-Amino-1MQ (5 mg Vial) Dosage Protocol
- Vial
- 5 mg 5-Amino-1MQ
- Add diluent
- 1 mL
- Concentration
- 5 mg/mL
- 1 unit (U-100)
- 50 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Once or twice per day (subcutaneous).
- Typical range
- 2.5–5 mg total per day (subcutaneous); the twice-daily alternative is 2.5 mg per administration.
Subcutaneous Protocol
| Phase | Daily Dose (mg) | Units (per injection) (mL) |
|---|---|---|
| Days 1–2 (Tolerance) | 2.5 mg (2500 mcg) | 50 units (0.50 mL) |
| Days 3+ (Standard) | 5 mg (5000 mcg) | 100 units (1.00 mL) |
| Alternative BID | 2.5 mg twice daily | 50 units (0.50 mL) × 2 |
How to mix
- Remove the vial from freezer storage (−20 °C / −4 °F) and allow to equilibrate at room temperature for 15–20 minutes.
- Draw 1.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved; solution should be clear (do not shake). Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; follow product-specific use-by instructions.
Dosing details
- Start: 2.5 mg once daily to assess tolerance.
- Target: 5 mg once daily or 2.5 mg twice daily (BID).
- Frequency: Once or twice per day (subcutaneous).
- Vial Duration: Single 5 mg vial lasts 1–2 days at 2.5–5 mg per day.
- Timing: Morning administration preferred; BID dosing may be split AM/PM.
Storage
- 5-Amino-1MQ is a small molecule. A generic peptide-storage guide cannot establish its shelf life, solubility, or sterile handling conditions.
- The exact material needs documented preparation and stability instructions. A mouse experiment that used a saline formulation cannot validate a bacteriostatic-water preparation or a multiweek refrigerated use-by limit for a different product.
Protocol source: PeptideDosages.com
Common questions
Is 5-Amino-1MQ a peptide?
No. It is a small-molecule chemical.
Is it an alternative to GLP-1 medicines?
No. It targets a different pathway and has no human comparison data.
Can it be combined with NAD products?
No study has established that a combination is safe or useful.
Related in Metabolic Health
Sources and further reading (5)
- Neelakantan H, et al. NNMT inhibitors reverse high fat diet-induced obesity in mice. Biochem Pharmacol, 2018.
- Sampson CM, et al. NNMT inhibition and reduced-calorie diet in obese mice. Sci Rep, 2021.
- Dimet-Wiley AL, et al. NNMT inhibition and muscle function in aged mice. Sci Rep, 2024.
- Awosemo O, et al. Pharmacokinetics and oral bioavailability of 5-amino-1MQ in rats.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).